RxDoctor Payments Data

Terry Baksh, MD

Internal Medicine · Norwich, CTNPI 1710962428

Payments from drug & device makers

$10,870in general payments, 2019–2025

Across 655 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$1K
  • AbbVie$1K
  • AstraZeneca$958
  • Boehringer Ingelheim$666
  • Astellas Pharma US Inc$579
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$10,61898%
  • Education$2522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,870 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$110,692
Medicare patients
358
Services billed
897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$92,590
JanuviaSitagliptin Phosphate37$50,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$23,935
TradjentaLinagliptin16$20,023
JanumetSitagliptin Phos/Metformin Hcl17$19,163
FarxigaDapagliflozin Propanediol16$14,434
Atorvastatin Calcium775$8,190
EliquisApixaban14$7,873
Rosuvastatin Calcium274$4,757
Losartan Potassium405$4,667
Omeprazole192$3,585
Metoprolol Succinate162$2,877
Levothyroxine Sodium327$2,872
Amlodipine Besylate440$2,780
SynthroidLevothyroxine Sodium28$2,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$666$112,61392 claims
MerckJanuvia, Janumet$88$69,74754 claims
GSKTrelegy Ellipta$1,342$23,93522 claims
AstraZenecaFarxiga$958$14,43416 claims
PfizerEliquis$123$7,87314 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$2,872327 claims
AbbVieSynthroid$1,098$2,09628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →